Elsevier

Drug and Alcohol Dependence

Volume 171, 1 February 2017, Pages 107-116
Drug and Alcohol Dependence

Review
A review: Fentanyl and non-pharmaceutical fentanyls

https://doi.org/10.1016/j.drugalcdep.2016.11.033Get rights and content

Highlights

  • Fentanyl and non-pharmaceutical fentanyls (NPF) are contributing to overdoses.

  • Overdoses may be more likely from fentanyl products due to their extreme potency.

  • Clinicians, patients and families should be educated about the dangers of fentanyl.

Abstract

Background

Fentanyl and non-pharmaceutical fentanyls (NPFs) have been responsible for numerous outbreaks of overdoses all over the United States since the 1970s. However, there has been a growing concern in recent years that NPFs are contributing to an alarming rise in the number of opioid-related overdoses.

Methods

The authors conducted a narrative review of the published and grey literature on fentanyl and NPFs in PubMed, Google Scholar, and Google using the following search terms: “fentanyl”, “non-pharmaceutical fentanyl”, “fentanyl analogs”, “fentanyl laced heroin” and “fentanyl overdose”. References from relevant publications and grey literature were also reviewed to identify additional citations for inclusion.

Results

The article reviews the emergence and misuse of fentanyl and NPFs, their clinical pharmacology, and the clinical management and prevention of fentanyl-related overdoses.

Conclusions

Fentanyl and NPFs may be contributing to the recent rise in overdose deaths in the United States. There is an urgent need to educate clinicians, researchers, and patients about this public health threat.

Introduction

In 2014, over 10 million individuals in the United States reported the use of illicit opioids as well as prescription opioids for non-medical reasons, contributing to drug-related overdose deaths which now outnumber traffic fatalities (Substance Abuse and Mental Health Services Administration (SAMHSA), 2014. Despite the concerted efforts to address the opioid crisis in this country, in recent years there has been a dramatic increase in overdoses from synthetic opioids, specifically fentanyl and related analogs (Drug Enforcement Administration (DEA); Rudd et al., 2016, Spies et al., 2016). From 2013 to 2014, the age-adjusted death rate from heroin, semi-synthetic opioids (i.e., oxycodone, hydrocodone), and synthetic opioids other than methadone increased by 26%, 9%, and 80%, respectively (Rudd et al., 2016). Evidence is now accumulating that drug manufacturers and dealers may be adding illicitly produced non-pharmaceutical fentanyl (NPF) to increase the potency of their products (Gladden et al., 2016, Hempstead and Yildirim, 2013, Peterson et al., 2016). While some individuals are using fentanyl and NPFs unintentionally through the use of fentanyl-laced heroin, others are knowingly seeking out fentanyl containing products due to the perception they are more desirable (Fernando, 1991, Mars et al., 2015).

The true extent of the illicit fentanyl and NPF use in the general population is difficult to ascertain, because routine toxicology screens will not detect synthetic opioids that have little structural homology to morphine and other commonly tested opioids. Nevertheless, fentanyl-related ED visits in the US increased from 9823 in 2004 to 20,034 in 2011, representing an increase of 104% (SAMHSA, 2013). At the same time, reports on state drug seizures from the National Forensic Laboratory Information System, a program of the (DEA, 2015a) office of diversion control, have noted an increase of fentanyl seizures by 259% from the second half of 2013 to the first half of 2014 (Centers for Disease Control and Prevention, 2015; DEA, 2015b). Fentanyl-related overdoses in Ohio, for example, increased from 84 in 2013 to 502 in 2014 (Spies et al., 2016). In Massachusetts, among the 1319 opioid-related death where toxicology results were available in 2015, 754 (57%) tested positive for fentanyl (Massachusetts Department of Public Health, 2016). Given the public health importance of this emerging problem, the aim of this review is to summarize the use and misuse of pharmaceutical fentanyl, clinical pharmacology of fentanyl, review of NPFs, and clinical management and prevention of fentanyl related overdoses.

Section snippets

The use and misuse of pharmaceutical fentanyl

For at least several thousand years, papaver somniferum has been cultivated by humans to harvest opium for its analgesic and medicinal properties. In the early 19th century, both morphine and codeine were isolated from opium, heralding an era of using pure alkoloids isolated from medicinal plants. From these starting materials, referred to as opiates, a variety of semi-synthetic opioids were created, including diacetyl-morphine (heroin) and oxycodone. In 1937, German scientists looking for an

Clinical pharmacology of fentanyl

Fentanyl is a full agonist at the mu-opioid receptor, and approximately 50–100 times more potent than morphine. Because fentanyl and NPFs are active in the sub–100 μg range, they are some of the most potent medications known to exist. Similar to other opioid agonists, fentanyl’s effects include analgesia, anxiolysis, euphoria, drowsiness, feelings of relaxation, respiratory depression, constipation, miosis, nausea, pruritus, and cough suppression, but also orthostatic hypotension, urinary

Review of non-pharmaceutical fentanyls (NPF)

In the winter of 1979, a series of apparent opioid overdoses were reported in Orange County, California, but no traces of heroin or opioids were identified on autopsy, yet injection drug paraphernalia were found near the bodies (syringes, needles, etc) and autopsy findings were consistent with opioid overdose (Henderson, 1988). In November of that same year, patients seeking entry into a methadone program in northern California were denied entry due to urines being negative for opioids (

Clinical management and prevention of fentanyl overdose

As in overdoses induced by other opioids, fentanyl-related overdoses are characterized principally by respiratory depression, accompanied by stupor and miosis (Boyer, 2012, Sporer, 1999). However, neither the absence of miosis nor the presence of mydriasis should be used to exclude the possibility of an overdose, as a substantial proportion of overdoses occur in the context of multiple drug ingestions (Hull et al., 2007). A variety of medical complications can result from the overdose,

Conclusions

For the past several decades, fentanyl has played an important role as an anesthetic agent and analgesic for severe pain due to its unique pharmacologic properties. However, there have also been numerous reports of inadvertent overuse, intentional misuse, and outbreaks of overdoses with fentanyl and NPFs. With the availability of large quantities of NPFs that can be produced with relative ease or ordered on-line, the growing number of overdoses attributed to these compounds is of considerable

Conflict of interest

No conflict declared.

Role of funding

Nothing declared.

Contributors

Conception and design (JS), literature review and data collection (JS, EH), writing (JS, EH), editing (JS, EH), approval of final version (JS, EH).

References (166)

  • M. Martin et al.

    China White epidemic: an eastern United States emergency department experience

    Ann. Emerg. Med.

    (1991)
  • Abel-Ollo, K., Talu, A., Vorobjov, S., Vals, K., Teder, P., Ahven, A., Denissov, G., 2011. 2011 National Report to the...
  • D.A. Algren et al.

    Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005–May 2006)

    J. Med. Toxicol.

    (2013)
  • A. Arens et al.

    Adulterated Xanax: A Case Series From San Francisco

    Poster Presented at the American College of Medical Toxicology (ACMT) Annual Scientific Meeting

    (2016)
  • D. Belz et al.

    Naloxone use in a tiered-response emergency medical services system

    Prehosp. Emerg. Care

    (2006)
  • O.J. Biedrzycki et al.

    Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: a case report and review of the literature

    Am. J. Forensic Med. Pathol.

    (2009)
  • I.A. Binswanger et al.

    Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009

    Ann. Intern. Med.

    (2013)
  • E.W. Boyer

    Management of opioid analgesic overdose

    N. Engl. J. Med.

    (2012)
  • J.L. Brittain

    China white: the bogus drug

    J. Toxicol. Clin. Toxicol.

    (1982)
  • J.E. Brodrick et al.

    Legal regimes surrounding naloxone access: considerations for prescribers

    Am. J. Drug Alcohol Abuse

    (2016)
  • E.O. Bryson et al.

    Addiction and substance abuse in anesthesiology

    Anesthesiology

    (2008)
  • I. Buajordet et al.

    Adverse events after naloxone treatment of episodes of suspected acute opioid overdose

    Eur. J. Emerg. Med.

    (2004)
  • G. Burns et al.

    Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?

    Clin. Toxicol. Phila

    (2016)
  • Centers for Disease Control and Prevention (CDC)

    Nonpharmaceutical fentanyl-related deaths–multiple states, april 2005-March 2007

    MMWR Morb. Mortal. Wkly. Rep.

    (2008)
  • Centers for Disease Control and Prevention, 2015. Increases in Fentanyl Drug Confiscations and Fentanyl-related...
  • J. Chandler

    Newly Popular and Deadly Fentanyl Pills are Being Made in Orange County’s Backyard

    (2016)
  • A.K. Chaturvedi et al.

    A death due to self-administered fentanyl

    J. Anal. Toxicol.

    (1990)
  • M. Coppola et al.

    AH-7921: a new synthetic opioid of abuse

    Drug Alcohol Rev.

    (2015)
  • S.M. Cunningham et al.

    Fatal intoxication with acetyl fentanyl

    J. Forensic Sci.

    (2015)
  • G. D’Onofrio et al.

    Emergency department-Initiated Buprenorphine/Naloxone treatment for opioid dependence: a randomized clinical trial

    JAMA

    (2015)
  • Drug Enforcement Administration

    2006 Heroin Domestic Monitor Program [WWW Document]

    (2007)
  • Drug Enforcement Administration

    Rules – 2010 – Final Rule: Control of Immediate Precursor Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance [WWW Document]

    (2010)
  • Drug Enforcement Administration

    2011 Heroin Domestic Monitor Program [WWW Document]

    (2013)
  • Drug Enforcement Administration, 2015a. National Heroin Threat Assessment Summary: DEA-DCT-DIR-039-15 [WWW Document]....
  • Drug Enforcement Administration, 2015b. Special Report: Opiates and related drugs reported in NFLIS, 2009-2014 [WWW...
  • Drug Enforcement Administration, 2015c. 2013 Heroin Domestic Monitor Program: DEA-DCW-DIR-059-15 [WWW Document]. URL...
  • Drug Enforcement Administration, 2016a. Rules - 2016 - Notice of Intent: Temporary Placement of Butyryl Fentanyl and...
  • Drug Enforcement Administration, 2016b. Counterfeit Prescription Pills Containing Fentanyls: A Global Threat:...
  • A. Dahan et al.

    Incidence, reversal, and prevention of opioid-induced respiratory depression

    Anesthesiology

    (2010)
  • S. Darke et al.

    The toxicology of heroin-related death: estimating survival times

    Addict. Abingdon Engl.

    (2016)
  • S. Darke et al.

    Heroin overdose: research and evidence-based intervention

    J. Urban Health Bull. N. Y. Acad. Med.

    (2003)
  • S. Darke et al.

    Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study

    J. Urban Health Bull. N. Y. Acad. Med.

    (2007)
  • V. De Vos

    Immobilisation of free-ranging wild animals using a new drug

    Vet. Rec.

    (1978)
  • J.S. Denton et al.

    An epidemic of illicit fentanyl deaths in cook county, illinois: september 2005 through april 2007

    J. Forensic Sci.

    (2008)
  • E. Digiusto et al.

    Serious adverse events in the australian national evaluation of pharmacotherapies for opioid dependence (NEPOD)

    Addict. Abingdon Engl.

    (2004)
  • Drug Enforcement Administration

    Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule

    Fed. Regist.

    (2010)
  • Drug Enforcement Administration (DEA), U.S. Department of Justice

    Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Interim rule with request for comments

    Fed. Regist.

    (2007)
  • Drug Enforcement Administration, Department of Justice

    Schedules of controlled substances: temporary placement of acetyl fentanyl into schedule I. Final order

    Fed. Regist.

    (2015)
  • K.M. Dunn et al.

    Opioid prescriptions for chronic pain and overdose: a cohort study

    Ann. Intern. Med.

    (2010)
  • L.E. Edinboro et al.

    Fatal fentanyl intoxication following excessive transdermal application

    J. Forensic Sci.

    (1997)
  • Cited by (282)

    View all citing articles on Scopus
    View full text